Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review
AJ Piper-Vallillo, LV Sequist… - Journal of Clinical …, 2020 - ascopubs.org
Since its approval in April 2018, osimertinib has been widely adopted as first-line therapy for
patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). Understanding …
patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). Understanding …
An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update
L Cerbone, JC Benitez, D Planchard… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction: Osimertinib is a third-generation anti-epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI), that irreversibly binds to mutant EGFR, specifically to the …
tyrosine kinase inhibitor (TKI), that irreversibly binds to mutant EGFR, specifically to the …